Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis

Terapevticheskii Arkhiv

Volumn 85, Issue 5, 2013, Pages 24-29

  Avdeeva, A S ^a   Aleksandrova, E N ^a   Novikov, A A ^a   Cherkasova, M V ^a   Panasyuk, E Yu ^a   Nasonov, E L ^a  

^a V A NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY   (Russian Federation)

Author keywords

Clinical Disease Activity Index (CDAI); Matrix metalloproteinase 3; Rheumatoid arthritis; Simplified Disease Activity Index (SDAI); Tocilizumab

Indexed keywords

ANTIRHEUMATIC AGENT; GLUCOCORTICOID; MONOCLONAL ANTIBODY; STROMELYSIN; TOCILIZUMAB;

ADULT; ARTICLE; BLOOD; BONE; CARTILAGE; ENZYME IMMUNOASSAY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; RECEIVER OPERATING CHARACTERISTIC; REMISSION; RHEUMATOID ARTHRITIS; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BONE AND BONES; CARTILAGE; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOENZYME TECHNIQUES; INFUSIONS, INTRAVENOUS; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; REMISSION INDUCTION; ROC CURVE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84880476546     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Mclnnes I., Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007; 7 (6): 429-442.
2. Barrage P., Mix K., Brinckerhoff C. Matrix met alloproteinases: role in arthritis. Front Biosci 2006; 11: 529-543.
3. Murphy G, Knauper V, Atkinson S. et al. Matrix met alloproteinases in arthritic disease. Arthritis Res 2002; 4 (Suppl 3): 39-49.
4. Flannery C. MMPs and ADAMTSs: functional studies. Front Biosci 2006; 11: 44-569.
5. Ribbens C, Andre B., Kaye O. et al. Synovial fluid matrix met alloproteinase 3 levels are increased in inflammatory arthritis whether erosive or not. Rheumatology 2000; 39: 1357-1365.
6. Bonassar L., Frank K, Murray J. et al. Grodzinsky: Changes in cartilage composition and physical properties due to stromelysin degradation. Arthritis Rheum 1995; 38 (2): 173-183.
7. Unemori E., Bair M., Bauer E. et al. Amento: Stromelysin expression regulates collagenase activation in human fibroblasts. Dissociable control of two met alloproteinases by interferon-gamma. J Biol Chem 1991; 266 (34): 23 477-23 482.
8. Ribbens C, Porras M., Franchimont N. et al. Increased matrix met alloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 2002;61: 161-166.
9. Kobayashi A., Naito S., Enomoto H. et al. Serum levels of matrix met alloproteinase 3 (stromelysin 1) for monitoring synovitis in rheumatoid arthritis. Arch Pathol Lab Med 2007; 131: 563-570.
10. Posthumus M., Limburg P., Westra J. et al. Serum matrix met alloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis. J Rheumatol 2002; 29: 883-889.
11. Yokoe L, Nishio S., Sato H., Kobayashi H. Comparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12 weeks. Mod Rheumatol 2011; 21: 710-714.
12. Gamero P., Thompson E, Woodworth T., Smolen J. Rapid and Sustained Improvement in Bone and Cartilage Turnover Markers With the Anti-Interleukin-6 Receptor Inhibitor Tocilizumab Plus Methotrexate in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate. Arthritis Rheum 2010; 62: 33-43.
13. Gibbons L., Hyrich K. Biologic therapy for rheumatoid arthritis. Clinical efficacy and predictors of response. Blodrugs 2009; 23: 111-124.
14. Catrina A., Lampa J., Emestam S. et al. Anti-tumour necrosis factor (TNF)-a therapy (etanercept) down-regulates serum matrix met alloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology 2002; 41: 484-489.
15. Cmkic M., Mansson B., Larsson L. et al. Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept. Arthritis Res Ther 2003; 5: R181-R185.
16. Young-Min S., Cawston T., Marshall N. et al. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum 2007; 56: 3236-3247.
17. Green M., Gough A., Devlin J. et al. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology 2003; 42: 83-88.
18. Mamehara A., Sugimoto T., Sudiyama D. et al. Serum matrix Met alloproteinase-3 as predictor of joint destruction in rheumatoid arthritis, treated with non-biological disease modifying antirheumatic drugs. Kobe J Med Sci 2010; 56: 98-107.
19. Nishimoto N., Kishimoto T. Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb Exp Pharmacol 2008; 181: 151-160.
20. Oldfield V, Dhillon S., Plosker G.L. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs 2009; 69: 609-632.
21. Frey N, Grange S., Woodworth T. Relationship between serum concentration of the interieukin-6 receptor inhibitor tocilizumab and C-reactive protein reduction in RA patients: 6 months data from a phase 3 study. Arthritis Rheum 2007; 56 (Suppl. 9): 148-149.
22. Choy E.H., Isenberg DA., Garrood T. et al. Therapeutic benefit of blocking interieukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002; 46: 3143-3150.
23. Nishimoto N, Terao K., Mima T. et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008; 112: 3959-3964.
24. Fransen J., Stuckt G., van Reil P.L.C.M. Rheumatoid arthritis measures Arthritis Rheum 2003; 49: 214-224.
25. Smolen J., Breedveld E.Schiff M, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 2003; 42: 244-257.
26. Shaver T.S., Anderson J.D., Weidensaul D.N. et al. The problem of rheumatoid arthritis disease activity and remission in clinical practice. J Rheumatol 2008; 35: 1015-1022.
27. Nishimoto N. Drug free remission after cessation of Actemra monotherapy (DREAM study) Ann Rheum Dis 2010; 69 (Suppl 3): 98.
28. Kaneko A., Kida D., Saito K. et al. Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI. Rheumatology Int. DOI10.1007/ S00296-011-2256-5
29. Urata Y., Uesato R., Tanaka D. et al. Treating to target matrix met alloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study. Ann Rheum Dis 2012; 71: 534-540.
30. Bang H., Luthke K., Gauliard A. et al. Mutated citrullinated vimentin as a candidate autoantigen for diagnosis and monitoring of disease activity in rheumatoid arthritis. Ann Rheum Dis 2006; 65 (Suppl II): 144.
31. Roland P., Mignot S., Bruns A. Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy. Arthritis ResTher2008;10:142.
32. Vizioli C., Viana V., Ribeiro A. Auto-antibody titers for monitoring rituximab therapy in rheumatoid arthritis Ann Rheum Dis 2012; 71(Suppl3):667.
33. Hama M., Uehara T., Takase K. et al. Power Doppler ultrasonography is useful for assessing disease activity and predicting joint destruction in rheumatoid arthritis patients receiving tocilizumab-preliminary data. Mod Rheumatol 2012; 32 (5): 1327-1333.